Shire Enters Strategic Licensing and Collaboration Agreement with ArmaGen

July 23, 2014: Shire announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

Read the full Shire press release and the full ArmaGen press release for details.

This entry was posted in News. Bookmark the permalink.

Comments are closed.